Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of genetic testing and analysis expert Illumina
So what: The third-quarter results posted this morning missed revised, lower earnings estimates by a penny but made up for it with a strong view of next-quarter sales. That said, management warned that revenues depend heavily on government sales, and you just never know what Uncle Sam's research budgets will look like next year.
Now what: Illumina's success did not inspire a rally among the company's chief rivals: Affymetrics
Interested in more info about Illumina? Click here to add it to My Watchlist.
Fool contributor Anders Bylund holds no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinion, but we all believe that considering a diverse range of insights makes us better investors. Check out Anders' holdings and bio, or follow him on Twitter and Google+. We have a disclosure policy.